Pharmaceutical Exec Requested Money from Son's Account as He Was Dying: Prosecutors

Jordan, who allegedly poisoned her 8-year-old son, Jude, with painkillers and other drugs, says she was protecting him

Gigi Jordan. Photo: Mary Altaffer/AP

Four-and-a-half-years after the death of Jude Mirra, his mother, former pharmaceutical executive Gigi Jordan, is on trial in Manhattan Supreme Court for allegedly giving the 8-year-old enough pills to kill him many times over.

On Thursday, Jordan’s former financial advisor Patrick Walsh told the jury that his client made a request to transfer money from her son’s account at 1:53 a.m. on Feb. 5, 2010. This request was made around the same time Jude, who Jordan says had autism, was dying in a room at the Peninsula Hotel in New York, according to prosecutors.

“Hi Pat,” Gigi Jordan wrote in an email to Walsh, according to the New York Post. “Can you please wire $125,000 to Bruce as requested below?”

She wanted the money transferred into one of her business accounts, prosecutors said.

“Gigi was an important client. A high-maintenance client,” Walsh said. “Many of the requests she would make could be considered unreasonable.”

Earlier in the trial, Dr. Edward Barbieri, a forensic pharmacologist, told jurors he found extremely high levels of Xanax in the child’s blood – 19 times what an adult would take, according to CBS New York.

He also said Jude was fed Prozac and another sedative that reduces blood pressure. The sedative was given to him at 20 to 40 times the adult dosage. In total, nine prescription drugs were found in his system, Dr. Barbieri said.

Jordan claims she killed Jude to save him from further sexual abuse by his biological father, Emil Tzekov. Tzekov denies the allegations and has never been charged.

Prosecutor Matt Bogdanos said in opening arguments that Jordan brought 5,918 pills with her to the hotel. Jordan claims she tried to kill herself after giving her son the drugs.

Want more stories like this?

Sign up for our newsletter and other special offers:

sign me up

Thank you for signing up!

Related Articles